PremiumCompany AnnouncementsAquestive Therapeutics Advances Product Pipeline and Market Access Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations Aquestive Therapeutics price target lowered to $7 from $8 at Raymond James PremiumCompany AnnouncementsAquestive Therapeutics Initiates Anaphylm NDA Filing Process Aquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97M Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c) PremiumCompany AnnouncementsAquestive Therapeutics Updates on Strategic Goals and Drug Progress Aquestive Therapeutics provides business update Aquestive Therapeutics receives FDA ODE for Libervant Buccal Film 
